Abstract
Blood stem cells have been used for decades to regenerate the bone marrow in patients with degenerative disorders of the blood system. Recent studies demonstrating the potential of blood stem cells to mediate the regeneration of tissues other than blood provide encouragement for their broader therapeutic use. Regulatory oversight plays a key role in ensuring the safety, quality and effectiveness of blood stem cells for regenerative therapy. This chapter outlines the current federal regulations governing therapeutic use of blood stem cells from a Canadian perspective.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bhatia M, Bonnet D, Murdoch B et al (1998) A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 4:1038–1045
Bjornson CR, Rietze RL, Reynolds BA et al (1999) Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283:534–537
Brazelton TR, Rossi FM, Keshet GI et al (2000) From marrow to brain: expression of neuronal phenotypes in adult mice. Science 290:1775–1779
Capoccia BJ, Robson DL, Levac KD et al (2009) Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 113:5340–5351
Casco-Robles MM, Yamada S, Miura T et al (2011) Expressing exogenous genes in newts by transgenesis. Nat Protoc 6:600–608
Chow SC, Liu JP (2004) Design and analysis of clinical trials: concepts and methodologies:, 2nd edn. Wiley, Hoboken
Clinical Trials Manual (http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/clini/cta_intro-eng.php)
Ferrari G, Cusella-De Angelis G, Coletta M et al (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279:1528–1530
Food and Drugs Act, Revised Statues of Canada, Interpretation, 1985, c-F-27 (http://laws-lois.justice.gc.ca/eng/acts/F-27/)
Food and Drug Regulations, Part C, Division 5, c. 870 (http://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c._870/)
Ford CE, Hamerton JL, Barnes DWH et al (1956) Cytological identification of radiation-chimeras. Nature 177:452–454
Friedman LM, Furberg CD, DeMets DL (2010) Fundamentals of clinical trials, 4th edn. Springer, New York
Guidance Document for Cell, Tissue and Organ Establishments; Safety of Human Cells, Tissues and Organs for Transplantation, Minister of Health (April 6 2009). http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cell/cto_gd_ld-eng.pdf. Accessed March 9 2011
Guidance for Industry: Cellular Therapy for Cardiac Disease (October 2010). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM164345.pdf. Accessed February 26 2011
Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy (March 1998). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm081670.pdf. Accessed February 26 2011
Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events (November 2006) http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078719.pdf. Accessed February 26 2011
Guidance for Industry: Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors (November 2006) http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078723.pdf. Accessed February 26 2011
Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) (April 2008) http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm092705.pdf. Accessed February 26 2011
Gussoni E, Soneoka Y, Strickland CD et al (1999) Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401:390–394
Hess D, Li L, Martin M et al (2003) Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 21:763–770
ICH Topic S6: Guidance for Industry: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals (July 1997) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_Guideline.pdf. Accessed March 28 2011
ICH Topic E9: Statistical Principles for Clinical Trials (February 1998) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf. Accessed March 28 2011
ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals) (June 2009) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/M3_R2/Step4/M3_R2__Guideline.pdf. Accessed March 28 2011
ICH Q5A R1, Viral Safety Evaluation of Biotechnology Products Derived From Cell Lines of Human and Animal Origin (September 1999)
ICH Q5D, Derivation and Characterization Cell Substrates Used for Production of Biotechnology/Biological Products (July 1997)
ICH S8, Immunotoxicity Studies for Human Pharmaceuticals (September 2005) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S8/Step4/S8_Guideline.pdf. Accessed March 28 2010
Jackson KA, Majka SM, Wang HW et al (2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest 107:1395–1402
Lagasse E, Connors H, Al-Dhalimy M et al (2000) Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6:1229–1234
LaBarge MA, Blau HM (2002) Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 111:589–601
Madeira C, Ribeiro SC, Pinheiro IS et al (2011) Gene delivery to human bone marrow mesenchymal stem cells by microporation. J Biotechnol 151:130–136
Mingozzi F, High KA (2007) Immune responses to AAV in clinical trials. Curr Gene Ther 7:316–324
Morrison SJ, Uchida N, Weissman IL (1995) The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 11:35–71
Neschadim A, McCart JA, Keating A et al (2007) A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant 13:1407–1416
Ogawa M (1994) Hematopoiesis. J Allergy Clin Immunol 94:645–650
Ogawa M (1993) Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844–2853
Orlic D, Kajstura J, Chimenti S et al (2001a) Bone marrow cells regenerate infarcted myocardium. Nature 410:701–705
Orlic D, Kajstura J, Chimenti S et al (2001b) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 98:10344–10349
Ruan J, Shen J, Wang Z et al (2011) Efficient preparation and labeling of human induced pluripotent stem cells by nanotechnology. Int J Nanomedicine 6:425–435
Safety of Human Cells, Tissues and Organs for Transplantation Regulations (June 2007) Canada Gazette II. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cto_regs_rias-reir-eng.pdf. Accessed March 9 2011
Sakurai H, Kawabata K, Sakurai F et al (2008) Innate immune response induced by gene delivery vectors. Int J Pharma 354:9–15
Sondergaard CS, Hess DA, Maxwell DJ et al (2010) Human cord blood progenitors with high aldehyde dehydrogenase activity improve vascular density in a model of acute myocardial infarction. J Transl Med 8:24
Till JE, McCulloch EA (1961) A direct measurement of radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14:213–222
Wang D, Nitsch D, Bakhai A (2006) Randomized clinical trials. In: Ward A (ed) Clinical trials: A practical guide to design, analysis and reporting. Remedica, London
Woltjen K, Michael IP, Mohseni P et al (2009) piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 458:766–770
Xu X, Geremia N, Bao F et al (2010) Schwann cell co-culture improves the therapeutic effect of bone marrow stromal cells on recovery in spinal cord-injured mice. Cell Transplant [Epub ahead of print]
Zhou P, Hohm S, Olusanya Y et al (2009) Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model. Hepatology 49:1992–2000
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Rosu-Myles, M., Gillham-Eisen, L.A., Agbanyo, F.R., Ganz, P.R. (2012). Regulatory Questions in the Development of Blood Stem Cell Products for Regenerative Therapy. In: Allan, D., Strunk, D. (eds) Regenerative Therapy Using Blood-Derived Stem Cells. Stem Cell Biology and Regenerative Medicine. Humana Press. https://doi.org/10.1007/978-1-61779-471-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-471-1_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-470-4
Online ISBN: 978-1-61779-471-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)